• A debate erupted over whether astaxanthin’s reported anti-inflammatory and possible lifespan-extending effects in mice are meaningful for humans, with initial skepticism that it merely acts as another Nrf2 up-regulator; a 2020 paper (PMC7759838) was cited showing it modulates uric-acid transporters, complicating the mechanism.

• Anecdotal user reports claim astaxanthin outperforms sulforaphane and curcumin for subjective inflammation and mild antidepressant effects, prompting discussion of cytokine-driven depression and curcumin’s MAOI activity.

• Locus Biosciences is running a Phase II trial of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail targeting multi-drug-resistant E. coli urinary-tract infections, with pre-clinical pipelines for Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus.

• Participants shared a Reuters article highlighting how safety fears have stalled a UN proposal to formally study solar-radiation-management geoengineering, framing the opposition as “don’t research because the risks are unknown.”

• A Twitter exchange between Richard Fuisz, Elon Musk, and John Carmack was noted, centering on a genomic-mutation-rate graphic that omitted copy-number variations, insertions, and deletions—caveats the author later acknowledged were lost in the viral thread.